drugset
drugset / Trial / NCT02211989

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 14332 CL Powder in Healthy Male Subjects

NCT02211989 ↗

Phase 1 Completed 53 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate safety, tolerability and pharmacokinetics, and pharmacodynamics of BI 14332 CL

Timeline

Start
2006-02
Primary completion
2006-04
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 14332 CL Unknown 0.5 mg Oral
Subject BI 14332 CL Unknown 200 mg Oral

Indications

No indication recorded.